Augmenting Scientific Discovery and Research Infrastructure in the UAB Regional Biocontainment Laboratory (SEBLAB)

增强 UAB 区域生物防护实验室 (SEBLAB) 的科学发现和研究基础设施

• 批准号: 10626482
• 负责人: Sixto Manuel Leal
• 金额: $ 433万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-23 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10626482
• 关键词: Accreditation; Alabama; Bioenergetics; Biomedical Research; Clinical; Containment; Cyclotrons; Development; Diagnostic; Diagnostic Imaging; Diagnostic tests; Disease Outbreaks; Equipment; Future; High Resolution Computed Tomography; In Vitro; Infrastructure; Investigation; Investments; Laboratories; Light; Microscope; Mission; Molecular; National Institute of Allergy and Infectious Disease; Output; Patient Care; Positron-Emission Tomography; Productivity; Public Health; Radioisotopes; Rapid diagnostics; Research; Research Infrastructure; Risk; Strategic Planning; Technology; Translating; Translational Research; Universities; Validation; biodefense; in vivo; innovation; new technology; noninvasive diagnosis; novel; pandemic disease; pandemic preparedness; pathogen; public health intervention; single cell sequencing; single photon emission computed tomography; ultra high resolution

Project Summary: The current proposal outlines a strategic plan to implement novel technologies within containment that will advance the NIAID mission to support pandemic preparedness and biomedical research on risk group III (RGIII) pathogens. This proposal focuses on the implementation of cutting edge equipment to advance in vitro (Aim1), in vivo (Aim2), and molecular investigation (Aim3) of high containment pathogens and also seeks to build upon the diagnostic expertise of the Scientific Director to establish a high containment molecular infrastructure capable of rapidly responding to future emerging pandemic threats with rapid diagnostic test development and real-world implementation for patient care and public health intervention. Innovations include: 1) First proposal seeking to acquire cutting edge equipment to increase scientific productivity at University of Alabama at Birmingham (UAB)’s SEBLAB, 2) Novel use of the Zeiss lattice light-sheet microscope within containment, 3) Innovative implementation of ultra-high resolution computed tomography and PET/SPECT capabilities enabling use of novel radionuclides generated by the nation’s largest TR24 cyclotron (UAB) for non-invasive diagnostic imaging research on RGIII pathogens, 4) Create the ability to perform bioenergetic analyses and single cell sequencing at SEBLAB, and 5) Implement molecular infrastructure within containment enabling rapid diagnostic test development and validation with a clear path to implementation in CLIA/CAP-accredited clinical and public health laboratories. Given the current pandemic, risks for future outbreaks, and rapid advancement of research technologies, investment in the UAB SEBLAB as outlined in the current proposal will translate into real-world impacts on pandemic preparedness and accelerate hyper-competitive basic biomedical and translational research output that advances our basic understanding and biodefense capabilities against high containment pathogens.

项目摘要：当前提案概述了实施新颖的战略计划 遏制技术将推进 NIAID 支持大流行病的使命 该提案的重点是针对 III 类风险 (RGIII) 病原体的准备和生物医学研究。 实施尖端设备以推进体外（Aim1）、体内（Aim2）和 对高遏制病原体进行分子研究（Aim3），并寻求建立在 科学总监的诊断专业知识建立了高含量的分子 能够快速应对未来新出现的流行病威胁的基础设施 用于患者护理和公共卫生的诊断测试开发和实际实施 创新包括： 1) 第一个提案寻求获得尖端设备 提高阿拉巴马大学伯明翰分校 (UAB) 的 SEBLAB 的科学生产力，2) 新颖 在安全壳内使用蔡司晶格光片显微镜，3) 创新实施 超高分辨率计算机断层扫描和 PET/SPECT 功能使得能够使用新颖的 由美国最大的 TR24 回旋加速器 (UAB) 产生的放射性核素，用于无创诊断 RGIII 病原体的成像研究，4) 创建进行生物能分析和 在 SEBLAB 进行单细胞测序，以及 5) 在安全壳内实施分子基础设施 实现快速诊断测试开发和验证，并提供明确的实施路径 鉴于当前的大流行，CLIA/CAP 认可的临床和公共卫生实验室面临风险。 未来的疫情爆发，以及研究技术的快速进步，对UAB的投资 当前提案中概述的 SEBLAB 将转化为对流行病的现实影响 做好准备并加速竞争激烈的基础生物医学和转化研究 提高我们对高水平的基本理解和生物防御能力的产出 遏制病原体。